Instructions for Penpulimab

[drug name]

Generic name: penpilimab

English name:Penpulimab

Product name: Aniko

【Drug Category】

AntiPD-1 monoclonal antibody (immune checkpoint inhibitor)

【Structural Features】

Panpilimab is a fully humanized monoclonal antibody based onIgG1 subtype. After Fc segment engineering, it can effectively reduce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This design helps reduce autoimmune-related side effects and optimize treatment safety.

【Indications】

Impilimab is currently approved in multiple countries and regions for the following indications:

1. Treatment of patients with relapsed or refractory classical Hodgkin lymphoma (cHL)

Especially suitable for patients with disease progression despite at least two previous systemic therapies. By enhancing the recognition and attack of tumor cells by the body's T cells, penpilimab has significantly improved the patient's remission rate and survival period.

2. Combined with chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC)

In clinical studies, penpilimab combined with chemotherapy showed excellent overall response rate (ORR) and progression-free survival (PFS) prolongation, providing a new treatment option for patients with advanced nasopharyngeal carcinoma.

In addition, penpilimab is actively expanding into the treatment of various solid tumors including non-small cell lung cancer (NSCLC), melanoma, hepatocellular carcinoma, etc.

【Mechanism of action】

Pimpilimab binds to programmed cell death receptors with high specificity-1 (PD-1), blocks the binding of PD-1 to its ligands PD-L1 and PD-L2, thereby restoring T cell-mediated anti-tumor immune responses. Compared with traditional IgG4-type PD-1 antibodies, the design based on IgG1 improves drug stability and reduces potential immune-related toxicity.

【Usage and Dosage】

For the combination of cisplatin or carboplatin and gemcitabine, the recommended dose of pembrolizumab is 200 g every three weeks until disease progression or unacceptable toxicity, for up to 24 months. The recommended single-agent pembrolizumab dose for previously treated or treated patients is 200 mg every 2 weeks until disease progression or unacceptable toxicity, for up to 24 months.

[Common adverse reactions]

Similar to otherPD-1 inhibitors, pembrolizumab may cause the following adverse reactions:

Immune-mediated adverse reactions: such as rash, thyroid dysfunction (hyperthyroidism or hypothyroidism), hepatitis, pneumonia and enteritis.

Infusion-related reactions: including fever, chills, rash, hypotension, etc.

General adverse reactions: such as fatigue, loss of appetite, joint pain, diarrhea, etc.

Most adverse reactions are grade 1-2and can be relieved by short-term treatment suspension or hormonal drug intervention.

【Contraindications】

It is contraindicated for those who are allergic to the active ingredients or excipients of ampilimab.

Use with caution in patients with active infections (such as active tuberculosis).

Pregnant or lactating women should use with caution and take effective contraceptive measures during treatment.

【Storage conditions】

Pimpilimab should be stored refrigerated at 2°C to 8°C, avoiding freezing and strong light exposure. The prepared solution should be used within the specified time to ensure efficacy and sterility.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC11189389/